Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 885.35 INR
Change Today 0.00 / 0.00%
Volume 0.0
GNP On Other Exchanges
Symbol
Exchange
OTC US
As of 7:05 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

glenmark pharmaceuticals ltd (GNP) Snapshot

Open
902.60
Previous Close
895.95
Day High
905.45
Day Low
875.55
52 Week High
04/15/15 - 940.75
52 Week Low
05/27/14 - 514.00
Market Cap
240.2B
Average Volume 10 Days
938.4K
EPS TTM
20.01
Shares Outstanding
271.3M
EX-Date
07/10/14
P/E TM
44.2x
Dividend
2.00
Dividend Yield
0.23%
Current Stock Chart for GLENMARK PHARMACEUTICALS LTD (GNP)

Related News

No related news articles were found.

glenmark pharmaceuticals ltd (GNP) Related Businessweek News

No Related Businessweek News Found

glenmark pharmaceuticals ltd (GNP) Details

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products. The company’s products include Crofelemer, an anti diarrheal drug for symptomatic relief of non-infectious diarrhoea in patients with HIV/AIDS on anti retro viral therapy; GRC 17536 for neuropathic pain and respiratory disorders; and GRC 27864, an orally bioavailable inhibitor of mPGES-1 to treat chronic inflammatory conditions, which is in Phase I trial. Its products also comprise Vatelizumab (GBR 500) that is in Phase II study for multiple sclerosis; GBR 900, which is in is Phase I trial for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor; and GBR 830, an anti-OX40 monoclonal antibody for autoimmune disorders. In addition, the company is involved in the formulations business that focuses on therapeutic areas, such as dermatology, anti-infectives, respiratory, cardiac, diabetes, gynecology, CNS, and oncology. It has operations in India, Latin America, Europe, the United States, and internationally. Glenmark Pharmaceuticals Limited was founded in 1977 and is headquartered in Mumbai, India.

11,000 Employees
Last Reported Date: 07/1/14
Founded in 1977

glenmark pharmaceuticals ltd (GNP) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: 57.1M
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 16.3M
Director of Corporate Affairs, Executive Dire...
Total Annual Compensation: 18.3M
Compensation as of Fiscal Year 2014.

glenmark pharmaceuticals ltd (GNP) Key Developments

Glenmark Pharmaceuticals Inc. Receives Tentative ANDA Approval for Rufinamide Tablets USP

Glenmark Pharmaceuticals Inc. has been granted tentative approval last week by the United States Food & Drug Administration (U.S. FDA) for its Rufinamide Tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel® Tablets of Eisai Inc. Under the terms of a settlement agreement between Glenmark and Eisai, Glenmark will be permitted to market this product in the United States on May 30, 2022 or potentially earlier under certain circumstances.

Indian Court Bars Glenmark Pharmaceuticals from Selling Merck Drug Copies

India's Supreme Court has barred Glenmark Pharmaceuticals from making and selling copies of Merck's diabetes drugs Januvia and Janumet. The court has, however, allowed Glenmark to continue to sell existing inventory, according to the document posted on the Supreme Court's website after a hearing. The decision against Glenmark comes two years after Switzerland's Novartis AG was denied patent protection for its cancer treatment Glivec in a landmark decision by India's Supreme Court that was widely seen as boosting the local generic drugs industry. Anti-diabetes drugs are the top-selling therapy area in India, where about 65 million people live with the disease and that number is expected to reach 100 million by 2030. Merck sued Glenmark in 2013 for infringing a patent it has on sitagliptin, the chemical compound in Januvia and Janumet, both of which the company has been selling in India since 2008.

Glenmark Pharmaceuticals Ltd., Board Meeting, Apr 17, 2015

Glenmark Pharmaceuticals Ltd., Board Meeting, Apr 17, 2015. Agenda: To decide to raise funds by way of issue of upto 10,800,000 equity shares of INR 1 each for cash to Aranda Investments (Mauritius) Pte Ltd.; and to decide to convene an extraordinary general meeting of the company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNP:IN 885.35 INR 0.00

GNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cadila Healthcare Ltd 1,752 INR -0.35
Jubilant Life Sciences Ltd 171.20 INR 0.00
Lannett Co Inc $55.39 USD +0.66
ScripsAmerica Inc $0.09 USD -0.0024
Taro Pharmaceutical Industries Ltd $139.17 USD -0.45
View Industry Companies
 

Industry Analysis

GNP

Industry Average

Valuation GNP Industry Range
Price/Earnings 46.9x
Price/Sales 3.7x
Price/Book 7.6x
Price/Cash Flow 32.4x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLENMARK PHARMACEUTICALS LTD, please visit www.glenmarkpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.